Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Meropenem trihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
2. What you need to know before you use Meropenem 3. How to use Meropenem 4. Possible side effects
5. How to store Meropenem 6. Contents of the pack and other information 1, WHAT MEROPENEM
IS AND WHAT IT IS USED FOR
Meropenem belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria, which can cause serious infections. + Infection affecting the lungs (pneumonia) + Lung and bronchial infections in patients suffering from cystic fibrosis + Complicated urinary tract infections + Complicated infections in the abdomen + Infections that you can catch during or after the delivery + Complicated skin and soft tissues infections + Acute bacterial infection of the brain (meningitis) Meropenem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection. Meropenem may be used to treat bacterial infection of the blood which might be associated with a type of infection mentioned above.
E MEROPENEM
Do not use Meropenem if : you are allergic (hypersensitive) to meropenem or any of the other ingredients of Meropenem (listed in Section 6 Further information). you are allergic (hypersensitive) to other antibiotics such as penicillins, cephalosporins or carbapenems as you may also be allergic to meropenem. Warnings and precautions Talk to your doctor, pharmacist or nurse before using Meropenem if: + you have health problems, such as liver or kidney problems. + you have had severe diarrhoea after taking other antibiotics. You may develop a positive test (Coombs test) which indicates the presence of antibodies that may destroy red blood cells. Your doctor will discuss this with you. If you are not sure if any of the above applies to you, talk to your doctor or nurse before using Meropenem. Other medicines and Meropenem
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is because Meropenem can affect the way some medicines work and
some medicines can have an effect on Meropenem In particular, tell your doctor or nurse if you are taking any of the following medicines:
Probenecid (used to treat gout). Valproic acid /Sodium valproate/ valpromide (used to treat epilepsy). Meropenem should not be used because it may decrease the effect of sodium valproate.
Oral anti-coagulant agent (used to treat or prevent blood clots).
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. It is preferable to avoid the use of meropenem during pregnancy. Your doctor will decide whether you should use meropenem. Itis important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving meropenem. Small amounts of this, medicine pass into the breast milk. Therefore, your doctor will decide whether you should use Meropenem while breast-feeding, Driving and using machines No studies on the effect on the ability to drive and use machines have been performed. However, Meropenem has been associated with headache, tingling or pricking skin (paraesthesiae) and involuntary muscle movements, leading the person's body to shake rapidly and uncontrollably (convulsions), that are usually accompained with a loss of consciousness and any of these could affect your ability to drive or operate machines. Meropenem contains sodium. Meropenem 500 mg: This medicinal product contains approximately 2.0 mEq of sodium per 500 mg dose which should be taken into consideration by patients on a controlled sodium diet. Meropenem 1.0 g: This medicinal product contains approximately 4.0 mEq of sodium per 1.0 g dose which should be taken into consideration by patients on acontrolled sodium diet. If you have a condition which requires you to monitor your sodium intake please inform your doctor, pharmacist or nurse.
MEROPENEM
from time to time. Changes in blood tests, including tests that show how well your kidney is working. A tingling feeling (pins and needles). Infections of the mouth or the vagina that are caused by a fungus (thrush). Inflammation of the bowel with diarrhoea. Sore veins where Meropenem is injected.
+
Like all medicines, Meropenem can cause side effects, although not everybody gets them. Tell your doctor immediately or if serious go to your nearest hospital emergency department if you get any of the following side effects. Severe allergic reactions Ifyou have a severe allergic reaction, stop having Meropenem and see a doctor straight away. You may need urgent medical treatment. The signs may include a sudden onset of: + Severe rash, itching or hives on the skin. + Swelling of the face, lips, tongue or other parts of the body. + Shortness of breath, wheezing or trouble breathing. Damage to red blood cells (not known) The signs include: + Being breathless when you do not expect it. + Red or brown urine
label and on the outer carton. The expiry date refers to the last day of that month. Do not store above 30°C. After reconstitution: The reconstituted solutions for intravenous injection or infusion should be used immediately. The time interval between the beginning of reconstitution and the end of intravenous injection or infusion should not exceed one hour. Do not freeze the reconstituted solution. The reconstituted solution is for single use only. The reconstituted solution should beclear to slight yellow transparent and should be free of any visible particles. From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately. If not used immediately in-use storage times and conditions are the responsibility of the user. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
If you notice any of the above, see a doctor straight away.
What Meropenem contains The active substance is meropenem. Each vial contains 500 mg anhydrous meropenem as meropenem trihydrate. The active substance is meropenem. Each vial contains 1 g anhydrous meropenem as meropenem trihydrate.
Other possible side effects:
Common (may affect up to 1 in 10 people) Abdominal (stomach) pain. Feeling sick (nausea). Being sick (vomiting).
Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure. Use in adults + The dose depends on the type of infection that you have, where the infection is in the body and how serious the infection is. Your doctor will decide on the dose that you need.
What Meropenem looks like and contents of the pack
Increased numbers of platelets in your blood (shown in a blood test). Changes in blood tests, including tests that show how well your liver is working. Uncommon (may affect up to 1 in 100 people! +
The dose for adults is usually between 500 mg (milligrams) and 2 g
Changes in your blood. These include reduced numbers of platelets
(which may make you bruise more easily), increased numbers of some
white blood cells, decreased numbers of other white cells and increased amounts of a substance called 'bilirubin'. Your doctor may do blood tests
(gram). You will usually receive a dose every 8 hours. However, you may
receive a dose less often if your kidneys do not work very well.
Use in children and adolescents The dose for children over 3 months old and up to 12 years of age is decided using the age and weight of the child. The usual dose is between 10 mg and 40 mg of Meropenem for each kilogram (kg) that the child weighs. A dose is usually given every 8 hours. Children who weigh over 50 kg will be given an adult dose. How to use Meropenem Meropenemwiill be given to you as an injection or infusion intoa large vein. Your doctor or nurse will normally give Meropenem to you. However, some patients, parents and carers are trained to give Meropenem at home. Instructions for doing this are provided in this leaflet (in the section called 'Instructions for giving Meropenem to yourself or someone else at home'). Always use Meropenem exactly as your doctor has told you. You should check with your doctor if you are not sure. Your injection should not be mixed with or added to solutions that contain other medicines. The injection may take about 5 minutes or between 15 and 30 minutes. Your doctor will tell you how to give Meropenem You should normally have your injections at the same times each day. If you use more Meropenem than you should If you accidentally use more than your prescribed dose, contact your doctor or nearest hospital straight away. If you forget to use Meropenem If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection. Do not have a double dose (two injections at the same time) to make up for a forgotten dose. If you stop using Meropenem Do not stop having Meropenem until your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor, Pharmacist or nurse.
The other ingredient is anhydrous sodium carbonate.
Diarrhoea. Headache. Skin rash, itchy skin. Pain and inflammation.
MEROPENEM Keep this medicine out of the sight and reach of children. Do not use Meropenem after the expiry date which is printed on the vial
Meropenem is a white to light yellow powder for solution for injection or infusion in vial. Pack size: 10 Vials in a Box. Marketing Authorisation Holder and Manufacturer Venus Pharma GmbH, Am Bahnhof, 1-3 Werne, D59368 GERMANY This leaflet was last revised in Mar. 2017 Advice/medical education Antibiotics are used to treat infections caused by bacteria. They have no
effect against infections caused by viruses. 'Sometimes an infection caused by bacteria does not respond to a course
of an antibiotic. One of the commonest reasons for this to occur is because the bacteria causing the infection are resistant to the antibiotic that is being taken. This means that they can survive and even multiply despite the antibiotic.
Bacteria can become resistant to antibiotics for many reasons. Using
antibiotics carefully can help to reduce the chance of bacteria becoming resistant to them. When your doctor prescribes a course of an antibiotic it is intended to treat only your current illness. Paying attention to the following advice will help
prevent the emergence of resistant bacteria that could stop the antibiotic working. 1. It is very important that you take the antibiotic at the right dose, at the
right times and for the right number of days. Read the instructions on the label and if you do not understand anything ask your doctor or pharmacist to explain. 2. You should not take an antibiotic unless it has been prescribed
specifically for you and you should use it only to treat the infection for which it was prescribed. 3. You should not take antibiotics that have been prescribed for other
people even if they had an infection that was similar to yours. 4. You should not give antibiotics that were prescribed for you to other people. 5. If you have any antibiotic left over when you have taken the course as directed by your doctor, you should take the remainder to a pharmacy for appropriate disposal Meropenem 500mg : PL 34985/0003. Meropenem 1 g : PL 34985/0004
(€14n4N41000/5087-05, C14/MMS00/5086-05
Tear
'THE FOLLOWING INFORMATION IS INTENDED FOR HEALTHCARE PROFESSIONALS ONLY: ions for giving urselfo ,
Dose of Meropenem
Some patients, parents and carers are trained to give Meropenem at home.
500 mg
'Amount of Water for Injections' needed for dilution 10 mi (millilitres)
1g (gram)
20 ml
15
Warning – You should only give this medicine to yourself or someone else at home after a doctor or nurse has trained you.
29
2
30
=
mi
40 ml
+ The medicine must be mixed with another liquid (the diluent). Your doctor will tell you how much of the diluent to use. + Use the medicine straight after preparing it. Do not freeze it. How to prepare this medicine
Meropenem 1 g Powder for Solution for injection or infusion, vial has a size of 20 ml and can be reconstituted with 20 ml Water for Injections. Please note: If your prescribed dose of Meropenem is more than 1g, you will need to use more than 'vial of Meropenem. You can then draw the liquid in the vials into the one syringe.
1. Wash your hands and dry them very well. Prepare a clean working area. 2. Remove the Meropenem bottle (vial) from the packaging. Check the vial
6. Put the needle of the syringe through the center of the grey rubber stopper and inject the recommended amount of Water for Injections into the vial or vials of Meropenem.
and the expiry date. Check that the vial is intact and has not been
damaged.
3. Remove the coloured cap and clean the grey rubber stopper with an
alcohol wipe. Allow the rubber stopper to 4. Connect a new sterile needle to a new sterile syringe, without touching the ends. 5. Draw up the recommended amount of sterile 'Water for Injections' into
the syringe. The amount of liquid that you need is shown below:
Meropenem 500 mg Powder for Solution for injection or infusion, vial has a size of 10 ml and can be reconstituted with 10 ml Water for Injections.
7. Remove the needle from the vial and shake the vial well for about 5 seconds, or until all the powder has dissolved. Clean the grey rubber
stopper once more with a new alcohol wipe and allow the rubber stopper to dry.
8. With the plunger of the syringe pushed fully into the syringe, put the needle back through the grey rubber stopper. You must then hold both the syringe and the vial and turn the vial upside down. 9. Keeping the end of the needle in the liquid, pull back the plunger and draw all the liquid in the vial into the syringe.
10. Remove the needle and syringe from the vial and throw the empty vial away ina safe place. 11. Hold the syringe upright, with the needle pointing upwards. Tap the
syringe so that any bubbles in the liquid rise to the top of the syringe. 12. Remove any air in the syringe by gently pushing the plunger until all the air has gone. 13. If you are using Meropenem at home, dispose of any needles and infusion lines that you have used in an appropriate way. If your doctor decides to stop your treatment, dispose of any unused Meropenem in an appropriate way. Please note:
An Intravenous infusion of meropenem may be prepared by directly constituting the contents of the vials with 0.9 % sodium chloride or 5% glucose solutions for infusion. Please follow the instructions that are stated below: To Meropenem 500 mg add 10 mi of the infusion diluent, then shake well to
reconstitute and then add this to the Diluent infusion bag.
To Meropenem 1 g add 20 ml of the infusion Diluent, then shake well to reconstitute and then add this to the Diluent infusion bag. The following concentration is achieved in the infusion bag when the
Giving the injection You can either give this medicine through a short cannula or venflon, or through a port or central line. Giving Meropenem through a short cannula or venflon 1, Remove the needle from the syringe and throw the needle away carefully in your sharps bin. 2. Wipe the end of the short cannula or venflon with an alcohol wipe and allow it to dry. Open the cap on your cannula and connect the syringe. 3. Slowly push the plunger of the syringe to give the antibiotic steadily over about 5 minutes. 4. Once you have finished giving the antibiotic and the syringe is empty, remove the syringe and use a flush as recommended by your doctor or nurse. 5. Close the cap of your cannula and carefully throw the syringe away in your sharps bin.
concentration of infusion
Giving Meropenem through a port or central line 1, Remove the cap on the port or line, clean the end of the line with an alcohol wipe and allow it to dry. 2. Connect the syringe and slowly push the plunger on the syringe to give the antibiotic steadily over about 5 minutes.
100 ml 0.9% NaCl
5 mg/ml
a flush as recommended by your doctor or nurse.
100 ml 5% Glucose |
5 mg/ml
1 gram
100 ml 0.9% NaCl
10 mg/ml
1 gram
100 ml 5% Glucose |
10 mg/ml
infusion is prepared:
Dose of Meropenem |
Infusion Diluent
500 mg 500 mg
Resulting
3. Once you have finished giving the antibiotic, remove the syringe and use
4. Place a new clean cap on your central line and carefully throw the syringe away in your sharps bin. Ver: 25-08-2011
Other changes in your blood. The symptoms include frequent infections, high temperature and sore throat. Your doctor may do blood tests from time to time. Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains.
Rare (may affect up to 1 in 1000 people) + Fits (convulsions). Frequency not known (cannot be estimated from available data) Serious hypersensitivity reactions involving fever, skin rash, and changes in the blood tests that check how the liver is working (increased levels of liver enzymes) and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes. These may be signs of a multi-organ sensitivity disorder known as DRESS syndrome. Reporting of side effects Ifyou get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National reporting system listed below. By reporting side effects, you can help provide more information on the safety of this medicine United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard
Meropenem 500 mg powder for solution for injection or infusion comes as injection containing 500mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Meropenem 500 mg powder for solution for injection or infusion is meropenem trihydrate.
Medicines with the same active substance, strength and form include: Meronem IV 500mg Powder for solution for injection or infusion, Meropenem 500 mg Powder for Solution for Injection or Infusion, Meropenem 500 mg powder for solution for injection/infusion. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Meropenem 500 mg powder for solution for injection or infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Meropenem is indicated for the treatment of the following infections in adults and children over 3 months of age (see sections 4.4 and 5.1) :
• Severe pneumonia, including hospital and ventilator-associated pneumonia.
• Broncho-pulmonary infections in cystic fibrosis
• Complicated urinary tract infections
• Complicated intra-abdominal infections
• Intra- and post-partum infections
• Complicated skin and soft tissue infections
• Acute bacterial meningitis
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Meropenem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
The tables below provide general recommendations for dosing.
The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.
A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp.), or very severe infections.
Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).
Adults and adolescents
Infections
Dose to be administered every 8 hours
Severe pneumonia including hospital and ventilator- associated pneumonia.
500 mg or 1 g
Broncho-pulmonary infections in cystic fibrosis
2 g
Complicated urinary tract infections
500 mg or 1 g
Complicated intra-abdominal infections
500 mg or 1 g
Intra- and post-partum infections
500 mg or 1 g
Complicated skin and soft tissue infections
500 mg or 1 g
Acute bacterial meningitis
2 g
Management of febrile neutropenic patients
1 g
Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3 and 6.6)
Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.
Renal Impairment
The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the application of these dose adjustments for a unit dose of 2 g.
Creatinine clearance (ml/min)
Dose (based on “unit” dose range of 500 mg or 1 g or 2 g, see table above
Frequency
26-50
one unit dose
every 12 hours
10-25
half of one unit
every 12 hours
<10
dose half of one unit dose
every 24 hours
Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.
There are no established dose recommendations for patients receiving peritoneal dialysis.
Hepatic impairment
No dose adjustment is necessary in patients with hepatic impairment (see section 4.4).
Dose in elderly patients
No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
Paediatric population
Children under 3 months of age
The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen (see section 5.2)
Children from 3 months to 11 years of age and up to 50 kg body weight
The recommended dose regimens are shown in the table below:
Infection
Dose to be administered every 8 hours
Severe pneumonia including hospital and ventilator- associated pneumonia.
10 or 20 mg/kg
Broncho-pulmonary infections in cystic fibrosis
40 mg/kg
Complicated urinary tract infections
10 or 20 mg/kg
Complicated intra-abdominal infections
10 or 20 mg/kg
Complicated skin and soft tissue infections
10 or 20 mg/kg
Acute bacterial meningitis
40 mg/kg
Management of febrile neutropenic patients
20 mg/kg
Children over 50 kg body weight
The adult dose should be administered
There is no experience in children with renal impairment.
Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see section 6.2, 6.3 and 6.6). Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to any other carbapenem antibacterial agent.
Severe hypersensitivity (e.g anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or cephalosporins).
The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.
Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. resistance
Resistance to penems of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp. varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in these bacteria to penems.
Hypersensitivity reactions
As with all beta-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported (see sections 4.3 and 4.8).
Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta- lactam antibiotics may also be hypersensitive to meropenem. Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.
If a severe allergic reaction occurs, the medicinal product should be discontinued and appropriate measures taken.
Antibiotic-associated colitis
Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents, including meropenem, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of meropenem (see section 4.8). Discontinuation of therapy with meropenem and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.
Seizures
Seizures have infrequently been reported during treatment with carbapenems, including meropenem (see section 4.8).
Hepatic function monitoring
Hepatic function should be closely monitored during treatment with meropenem due to the risk of hepatic toxicity (hepatic dysfunction with cholestasis and cytolysis) (see section 4.8).
Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem. There is no dose adjustment necessary (see section 4.2).
Direct antiglobulin test (Coombs test) seroconversion
A positive direct or indirect Coombs test may develop during treatment with meropenem.
Concomitant use with valproic acid/sodium valproate/valpromide
The concomitant use of meropenem and valproic acid/sodium valproate/valpromide is not recommended (see section 4.5).
Paediatric population
Meropenem is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available data. All reports received were consistent with events observed in the adult population.
Meropenem contains sodium.
Meropenem 500 mg: This medicinal product contains approximately 2.0 mEq of sodium per 500 mg dose which should be taken into consideration by patients on a controlled sodium diet.
Meropenem 1.0 g: This medicinal product contains approximately 4.0 mEq of sodium per 1.0 g dose which should be taken into consideration by patients on a controlled sodium diet.
No specific medicinal product interaction studies other than probenecid were conducted. Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half- life and plasma concentration of meropenem. Caution is required if probenecid is co-administered with meropenem.
The potential effect of meropenem on the protein binding of other medicinal products or metabolism has not been studied. However, the protein binding is so low that no interactions with other compounds would be expected on the basis of this mechanism.
Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60-100 % decrease in valproic acid levels in about two days. Due to the rapid onset and the extent of the decrease, co-administration of valproic acid/ sodium valproate/valpromide with carbapenem agents is not considered to be manageable and therefore should be avoided (see section 4.4).
Oral anti-coagulants
Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects. There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.
Pregnancy
There are no or limited amount of data from the use of meropenem in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3)
As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.
Lactation
Small amounts of meropenem have been reported to be excreted in human milk. Meropenem should not be used in breast-feeding women unless the potential benefit for the mother justifies the potential risk to the baby.
No studies on the effect on the ability to drive and use machines have been performed. However, when driving or operating machines, it should be taken into account that headache, paraesthesiae and convulsions have been reported for meropenem.
Summary of the safety profile
In a review of 4,872 patients with 5,026 meropenem treatment exposures, meropenem-related adverse reactions most frequently reported were diarrhoea (2.3 %), rash (1.4 %), nausea/vomiting (1.4 %) and injection site inflammation (1.1 %). The most commonly reported meropenem-related laboratory adverse events were thrombocytosis (1.6 %) and increased hepatic enzymes (1.5-4.3 %).
Tabulated risk of adverse reactions
In the table below all adverse reactions are listed by system organ class and frequency: very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (< 1/10,000) Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
System Organ Class
Frequency
Event
Infections and infestations
Uncommon
oral and vaginal candidiasis
Blood and lymphatic system disorders
Common
thrombocythaemia
Uncommon
eosinophilia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis, haemolytic anaemia.
Immune system disorders
Uncommon
angioedema, anaphylaxis (see sections 4.3 and 4.4)
Nervous system disorders
Common
headache
Uncommon
paraesthesiae
Rare
convulsions (see section 4.4)
Gastrointestinal disorders
Common
diarrhoea, vomiting, nausea, abdominal pain
Uncommon
antibiotic-associated colitis (see section
4.4)
Hepato-biliary disorders
Common
transaminases increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased.
Uncommon
blood bilirubin increased
Skin and subcutaneous tissue disorders
Common
rash, pruritis
Uncommon
urticaria toxic epidermal necrolysis, Stevens Johnson syndrome, erythema, multiforme
Unknown
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome)
Renal and urinary disorders
Uncommon
blood creatinine increased, blood urea increased
General disorders and administration site conditions
Common
inflammation, pain
Uncommon
thrombophlebitis pain at the injection site
Paediatric population
Meropenem is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available data. All reports received were consistent with events observed in the adult population.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National reporting system listed below.
United Kingdom
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described in section 4.2. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described in section 4.8, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.
In individuals with normal renal function, rapid renal elimination will occur. Haemodialysis will remove meropenem and its metabolite.
Ask anything about Meropenem 500 mg powder for solution for injection or infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.